Deep Potential and Dongyangguang Establish Joint Laboratories for AI4S-Driven Innovation in Biopharma and Advanced Materials

Aug 29, 2024 18:18 CST Updated 18:18

DP Technology

Simulation R&D Platform Developer

August 28, 2024DP Technology and Dongyang Light Co., Ltd. Jointly Establish Two Major R&D Laboratories for Biomedicine and New Materials, and Hold Inauguration CeremonyDP Technology and Dongyang Light Join Hands to Establish a Biomedical Joint Laboratory Focusing on High-Value R&D Scenarios and Technical Bottlenecks in the Biomedical Field. This collaboration Aims to Drive Technological Innovation from the Source to Industrial Application, Forming a Complete Closed Loop. Together, They Explore the Transformation and Validation of Cutting-Edge AI Technologies in the Biomedical Industry; The Joint AI4S New Materials Research Laboratory Established by Both Parties Aims to Empower Dongyang Light's Electronic New Materials Industry with AI, Enhancing R&D Efficiency and Success Rates, Building an Automated and Digital Intelligent Manufacturing System, Accelerating Product Promotion and Customer Expansion; By Integrating Resources, They Jointly Tackle Industry Pain Points, Complement Each Other's Strengths, and Achieve Mutual Benefits for Development.

Wei Jie Sun, Founder and CEO of DP Technology, Qin Li, Vice President, Xiao Min Zhang, Chief Pharmaceutical Officer, Xiao Bing Li, General Manager of the Biomedical Division, Xiao Xu Wang, General Manager of the Energy Materials Division; Xin Hua Deng, Director of Dongyangguang Group and Dean of the Research Institute, Lin Zhou, Supervisor of Dongyangguang Group and Minister of Strategic Planning, Ying Jun Zhang, Chairman of Guangdong Dongyangguang Pharmaceutical Co., Ltd., and Huo Qiang Tang, Dean of Dongyangguang New Energy Research Institute, attended the signing and unveiling ceremony of the joint laboratory.

In the field of biomedicine, since 2023, DP Technology and Dongyangguang have held multiple discussions on AI research and development, jointly committing to leveraging AI technology to drive innovation in drug discovery. The core of this joint laboratory lies in utilizing the AI technology platform provided by DP Technology to offer comprehensive support and solutions for target screening and preclinical drug research. Both parties will work together to enhance the efficiency and accuracy of drug discovery, thereby accelerating the process of new drug identification and development. DP Technology’s AI platform will provide the joint laboratory with robust computational power and data analysis capabilities, assisting researchers in more rapidly identifying potential drug targets and enabling more precise simulations and predictions during the preclinical research stage. This will significantly shorten the drug discovery cycle and effectively reduce the cost of drug design.

In the field of electronic new materials, Dongyang Guang will leverage the efficient AI for Science platform and tools developed by DP Technology to empower electronic new materials as a strategic development direction. It is committed to building an intelligent computing platform for electronic new materials and constructing an industry ecosystem that integrates electronic materials with AI. Dongyang Guang and DP Technology have established a joint laboratory, which will quickly help Dongyang Guang cultivate an AI technical team, build an AI foundational platform, and promote technological innovation in electronic new materials. The two parties have made phased progress in AI application scenarios such as the screening of main solutes in electrolytes and the formula design of cathode materials. Going forward, they will jointly address industry challenges such as energy conservation and consumption reduction in the electrode foil industry, life prediction of capacitors and storage batteries, and process optimization of new energy storage materials.

Guangdong Dongyangguang Pharmaceutical Co., Ltd. (hereinafter referred to as Dongyangguang Pharma), a leading player in China's anti-influenza sector, boasts KeWei® as the top brand of oseltamivir phosphate. In February this year, it received three certifications from the internationally authoritative institution Frost & Sullivan: "The World's Largest Oseltamivir Production Base," "The World's Top Cumulative Five-Year Oseltamivir Output," and "The World's Top Cumulative Five-Year Oseltamivir Shipment Volume." Since its establishment, Dongyangguang Pharma has been driven by innovation and internationalization, with excellent commercial capabilities guiding the company’s development. It has strategically positioned itself in the research and development of three major therapeutic areas: infectious diseases, chronic diseases, and oncology. Currently, it holds over 140 approved drugs globally, with more than 100 drugs in the pipeline, including over 40 innovative first-class drugs. Among these, three innovative drugs have been submitted for marketing approval, while ten are in Phase II and III clinical trials. The company has filed over 2,400 patent applications, with more than 1,300 authorized patents. Its team of over 1,200 researchers provides robust support for its product pipeline. It also operates the "National Key Laboratory for Anti-Infective New Drug Research and Development" approved by the Ministry of Science and Technology, marking Dongguan's first national-level corporate key laboratory.

At the same time, Dongyang Guang Electronics Materials has adhered to independent innovation for more than 20 years, focusing on the fields of electronic components and chemical new materials. It has built four major industrial clusters: electronic components, high-end aluminum foil, chemical new materials, and new energy materials; received over 100 national and provincial honors, applied for more than 1,200 patents, established four major research institutes in Dongguan, Guangzhou, Dongyang, and Japan, possesses a complete R&D platform, accumulated rich R&D experience and high-quality reliable data, and has the foundation for AI-empowered development.

As a leader and practitioner of the "AI for Science" research paradigm, DP Technology has published multiple related works in the field of drug design in international top journals since its establishment. In April this year, DP Technology released the scientific large model system Deep Potential · Universe®, including the DPA molecular simulation large model, Uni-Mol molecular conformation large model, Uni-Fold protein folding large model, Uni-RNA gene sequence large model, and Uni-SMART multimodal scientific literature large model, among others. These models not only reach SOTA levels in their respective fields but have also been integrated into DP Technology's product platform, bridging the "innovation to implementation" pathway. Particularly in the biopharmaceutical field, DP Technology’s Hermite® drug computational design platform and RiDYMO® difficult-to-drug target R&D platform have partnered with multiple clients, more broadly combining the advanced research paradigm of AI for Science with drug development. Through DP Technology’s solutions, the R&D investment efficiency and decision-making quality of partners are enhanced.

On the other hand, DP Technology, targeting the battery field, has developed the Piloteye® Battery Design Automation Platform with "microscale industrial design and simulation" as the entry point. This platform integrates a series of innovative algorithms driven by AI for Science principles and data into the battery research and development process. Focusing on organic materials, inorganic materials, and literature retrieval related to battery R&D, Piloteye® has undergone rapid updates with the support of large models. Based on the DPA molecular simulation large model, Piloteye® has achieved numerous breakthroughs in the R&D of inorganic materials for batteries. The Uni-Mol molecular conformation large model has helped Piloteye® shorten the development cycle for organic materials. In practical cases, DP Technology has already assisted partners in applying new electrolyte molecules to novel batteries, enhancing the overall stability of the electrolyte. Additionally, the Piloteye® product features a material database module. With the help of the Uni-SMART scientific literature multimodal large model, it extracts valuable data from patents and literature, organically integrating computational simulation data with experimental data for easy access and model training. Currently, DP Technology has accumulated rich and cutting-edge academic achievements in cathode materials, anode materials, electrolytes, and electrochemical simulations, forming successful demonstrations through cooperation with multiple leading companies in the upstream and downstream battery industry.

Dongyang Light stated"The establishment of the joint laboratory between Dongyangguang and DP Technology marks the combination of the strengths of the two companies in their respective fields. With its strong R&D foundation in areas such as biomedicine and electronic materials, Dongyangguang, together with DP Technology's AI platform technology, is expected to significantly improve R&D efficiency and accelerate the discovery of new targets. Currently, the Pharmaceutical Research Institute has initiated the development project of preclinical candidate compounds, which is expected to expedite the development process of target indications. Additionally, relying on DP Technology's intelligent R&D platform and a smart scientific literature database powered by multimodal large models, the R&D team will also see a significant enhancement in overall literature research efficiency and intelligent R&D capabilities."

DP Technology stated"HD Sunshine has more than two decades of deep cultivation in the industry, always embracing technological innovation and progress. As a leader and advocate of AI4S, DP Technology maintains an open attitude towards industrial chain cooperation, understanding real needs and solving real problems. We believe that our cutting-edge breakthroughs in the AI for Science field and unique accumulation in the innovative ecosystem will better enhance the quality and efficiency of HD Sunshine's R&D processes. We look forward to further exchanges and interactions between both parties in more collaborative projects and application scenarios, jointly deepening the layout of industrial cooperation, and helping each other achieve leaps in technology and commercialization."

DP Technology and Dongyangguang Join Hands to Establish Joint Laboratory, Marking the Start of Comprehensive and In-Depth CollaborationThe joint laboratory co-founded by DP Technology and Dongyangguang marks the beginning of comprehensive and in-depth cooperation between the two parties in their respective areas of expertise. As a company with rich experience and deep accumulation in pharmaceutical R&D and electronic new materials, Dongyangguang Group will provide the joint lab with abundant industry resources and practical experience. Meanwhile, DP Technology will leverage its strengths in AI technology to offer advanced technical platforms and algorithmic support for the lab. The collaboration between the two sides will not be limited to the technical level but will also cover talent cultivation, project cooperation, and more, forming an all-around cooperative model. This partnership will bring new development opportunities to both the pharmaceutical and new materials industries, driving technological advancement and industrial upgrading across the entire sector.

In the future, DP Technology and Dongyang Light will jointly explore new heights in the research and development and innovative applications of AI platform technology in the biomedicine and new materials fields, creating a new model for AI-driven R&D. DP Technology and Dongyang Light will continue to strengthen multi-modal collaborations with national research institutes and leading AI enterprises, striving to build a top industrial research institute in China and internationally, leading a new wave of AI empowerment and innovation.

Recommended Follow

About DP Technology

DP Technology is a leader and practitioner of the "AI for Science" research paradigm. AI for Science involves using AI to learn a series of scientific principles and knowledge, and further addressing key issues in scientific research and industrial R&D.

DP Technology, relying on its deep cultivation in interdisciplinary fields, has built "Deep Potential · Cosmic Insight^®"AI for Science Large Model System ushers the research methods of numerous disciplines from the 'experimental trial and error/computer' era into the 'pre-trained model era,' using 'micro-scale industrial design and simulation' as the entry point to create...Bohrium^®Bohr^®Research Space Station, Hermite^®Drug Computational Design Platform, RiDYMO^®Difficult-to-Drug Target R&D Platform and Piloteye^®Research and industrial R&D infrastructures such as battery design automation platforms have formed the "innovation - implementation" chain and open ecosystem for AI for Science, empowering "thousands of industries." It builds a new generation of industrial design and simulation systems for the most fundamental biomedical, energy, materials, and information science and engineering research in human economic development.

DP Technology is a national high-tech enterprise and a national specialized and new "little giant" enterprise, with research and development centers located in cities such as Beijing, Shanghai, and Shenzhen.The scientific research and technology team is led by an academician of the Chinese Academy of Sciences, bringing together over a hundred outstanding young scientists and engineers from various fields such as mathematics, physics, chemistry, biology, materials, and computer science. Among the company's members, more than 35% hold a Ph.D. or are postdoctoral researchers.Core members have won the "Gordon Bell Prize," the highest award in the field of global high-performance computing in 2020. Their related work was selected as one of China's top ten scientific and technological advances in 2020 and one of the ten major technological breakthroughs in the global AI field.